Novel drug shows hemodynamic benefits in patients across heart failure spectrum

MUNICH — A novel oral relaxin receptor agonist was well tolerated and had favorable effects on hemodynamics in patients with heart failure across the ejection fraction spectrum, researchers reported. For the phase 2b LUMINARA trial, presented at the European Society of Cardiology Congress and simultaneously published in Circulation, researchers evaluated AZD5462 (AstraZeneca) in two